Assistant
RAG-Based Approaches for Life Science Applications
Why Vector Search Alone Is Not Enough for Pharmaceutical and R&D AI
Scientific data is complex, fast evolving, and difficult to search. Many Life Sciences teams turn to vector based search to quickly enable semantic search and test RAG strategies for LLMs. But in high-stakes environments where accuracy and explainability matter, vector search alone is not enough. Vector methods often struggle to distinguish scientific concepts that appear close in vector space. This is where expert curated ontologies dramatically strengthen search quality, context, and precision.
What you will learn in this video:
- How vector based search helps kickstart RAG and LLM implementations
- Where vector search falls short in scientific and regulatory contexts
- Why combining Neural Search with ontology based semantic search delivers superior accuracy
- How a hybrid approach improves grounding, transparency, and scientific insight
See how Life Sciences organizations achieve more accurate RAG pipelines by combining AI with trusted scientific structure.
Watch the on-demand webinar
What This Webinar Covers
How vector-based search accelerates RAG and LLM implementation in life sciences: The webinar opens with an honest assessment of what vector search does well: rapid deployment, semantic flexibility, and the ability to surface relevant content without manual keyword optimization. For organizations beginning their life sciences AI journey, vector-based retrieval provides a practical starting point that delivers immediate value, particularly for general knowledge management tasks across research and commercial functions.
Where vector search breaks down in scientific and regulatory contexts: The session then examines the structural limitations: concept disambiguation failures, synonym explosion in biological nomenclature, regulatory taxonomy mismatches, and the explainability gap that makes vector-only RAG difficult to validate in GxP environments. Life sciences AI that cannot explain why it retrieved a specific document, and which ontology-defined concept triggered that retrieval, is difficult to trust in any workflow that feeds regulatory submissions, clinical decisions, or safety assessments.
Why combining neural search with ontology-based semantic search delivers superior accuracy: This is the core technical argument: how Sinequa’s hybrid approach applies ontology-based entity recognition at indexing time, combines structured and unstructured content retrieval in a single query, and produces RAG outputs where every passage is grounded in identified scientific concepts rather than vector proximity alone.
How the hybrid approach improves grounding, transparency, and scientific insight: The session closes with the operational implications: faster research cycles, higher-quality regulatory dossier preparation, improved clinical literature synthesis, and the auditability requirements under 21 CFR Part 11 and GxP frameworks that make explainable retrieval a compliance necessity — not just a quality improvement.
Life Sciences RAG Requirements That Generic Platforms Cannot Meet
Organizations deploying AI in pharmaceutical, biotech, or medical device environments face a set of requirements that go well beyond what general-purpose enterprise RAG platforms were designed to address.
- Regulatory compliance: Retrieval and generation outputs in GxP workflows must be auditable. The system must be able to show which document was retrieved, on what basis, and what regulatory classification applies. 21 CFR Part 11, GxP, FDA/EMA submission standards, and GDPR each impose specific traceability requirements that vector-only retrieval cannot satisfy.
- Multi-source data unification: Life sciences knowledge is distributed across ELN (Electronic Lab Notebooks), LIMS (Laboratory Information Management Systems), CDS (Clinical Data Systems), regulatory submission management platforms, scientific literature databases (PubMed, EMBASE), patent databases, and internal research repositories.
- Scientific synonym and alias resolution: A single drug target may be referenced by dozens of gene aliases, protein names, and compound identifiers across different research databases and publication contexts. Without ontology-based synonym resolution at the indexing layer, RAG systems miss relevant content that exists in the data but cannot be reached through keyword or vector proximity alone.
- Scalability and security: Fifty percent of the world’s leading pharmaceutical companies have deployed Sinequa at enterprise scale — tens of thousands of users, petabytes of scientific content, global multi-site operations with role-based access controls inherited from source systems at the document level. Research scientists see compounds relevant to their programs. Regulatory affairs teams access dossier content aligned to their submissions. AI-generated answers never surface information beyond what the querying user is authorized to access.
From RAG to Agentic AI in Life Sciences
The transition from AI assistants to agentic AI — systems that can take multi-step actions, not just answer questions — is already underway in life sciences. AI agents that can autonomously monitor competitive intelligence, flag regulatory changes affecting active submissions, or synthesize emerging clinical evidence for a specified indication are within reach. But they are only trustworthy when the retrieval foundation underneath them is scientifically precise, domain-aware, and auditable. The hybrid neural + ontology approach this webinar presents is not just the right answer for today’s RAG implementations. It is the prerequisite architecture for life sciences AI that can operate autonomously in regulated environments.
Frequently Asked Questions (FAQ)
RAG (Retrieval-Augmented Generation) is the AI architecture where a language model generates answers based on content retrieved from an organization’s own documents, rather than relying solely on the model’s training data. In most enterprise contexts, vector-based retrieval — which finds documents by mathematical similarity in embedding space — works adequately. Life sciences requires a more sophisticated approach because scientific concepts that are critically different in meaning often appear similar in vector space: drug targets and off-target effects, Phase II and Phase III results, agonists and antagonists. Sinequa addresses this by combining neural search with ontology-based entity recognition — expert-curated concept taxonomies that define exactly which documents are relevant to a specific scientific query, independent of surface-level textual similarity.
Scientific ontologies are expert-curated knowledge graphs that define the vocabulary of a domain — gene names and aliases, compound identifiers, disease terminology across ICD-10, MedDRA, and SNOMED, regulatory concept hierarchies, and the relationships between all of them. When applied at document indexing time, ontology-based entity recognition enriches every document with structured concept tags that enable precise retrieval regardless of how a query is phrased or which synonym a researcher uses. The result is a RAG pipeline where retrieval is grounded in scientific meaning, not just statistical word proximity — which is the difference between an AI answer a researcher can act on and one they must manually verify.
Fifty percent of the world’s leading pharmaceutical companies have deployed Sinequa, including Pfizer, AstraZeneca, GSK, Novartis, Bristol Myers Squibb, UCB, Takeda, and Astellas. UCB documented $143M in annual savings and 20% faster clinical analysis after deploying Sinequa across 5,250 users. AstraZeneca uses Sinequa to unify discovery research, clinical documentation, and regulatory submission content into a single AI-searchable knowledge layer. These organizations chose Sinequa specifically because its hybrid neural + ontology retrieval approach delivers the scientific precision and regulatory auditability that general-purpose AI platforms cannot provide.
AI applications in pharmaceutical and biotech environments that touch GxP workflows, regulatory submissions, or safety data must meet auditability standards defined by 21 CFR Part 11, GxP guidelines, FDA/EMA submission requirements, and GDPR. Sinequa’s ontology-enriched retrieval provides document-level and concept-level traceability: every AI-generated answer cites the specific documents retrieved, the scientific concepts that triggered retrieval, and the source system from which the content originated. This audit trail is essential for validating AI outputs in regulated environments and for demonstrating to regulatory reviewers that AI-assisted dossier preparation or clinical literature synthesis meets applicable compliance standards.
Sinequa connects all major life sciences data sources through 200+ enterprise connectors: ELN (Electronic Lab Notebooks), LIMS (Laboratory Information Management Systems), CDS (Clinical Data Systems), regulatory submission management platforms, scientific literature databases (PubMed, EMBASE), patent databases, SharePoint, Teams, and internal research repositories. All content is indexed with ontology-based entity recognition applied consistently — meaning a single query surfaces relevant data from internal studies, published literature, competitive intelligence, and regulatory precedent simultaneously. Source system access controls are inherited at the document level, ensuring every AI answer is scoped to the querying user’s authorization.
Share
